anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Panhematin
Trial phase: Phase 2
SMILES: C=CC1=C(C)c2cc3[n-]c(cc4[n-]c(cc5nc(cc1n2)C(C)=C5C=C)c(C)c4CCC(=O)O)c(CCC(=O)O)c3C.[Cl-].[Fe+3]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Panhematin treatment arm
Eligibility criteria:
Inclusion Criteria:

A patient will be eligible for study participation if all of the following criteria are met:

The patient must sign and date the IRB/IEC approved Informed Consent Form/HIPAA Authorization prior to study participation.
Patient is at least 18 years of age.

If female:

Patient, either male or female, is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if of childbearing potential, must comply with an effective method of birth control acceptable to the Investigator during the study (oral contraceptives, Depo-Provera, intra-uterine device), for at least 1 month prior to enrollment and for 1 month following the completion of the study.
Patient is not breastfeeding.
Patient of childbearing potential must have a negative urine or serum pregnancy test during the screening period.
Patient has a diagnosis of low- or intermediate-1 risk MDS, as determined by the International Prognostic Scoring (IPSS) (score of 0-1).
Patient must be transfusion dependent (i.e., received ≥ 2 units over an 8-week period prior to registration) or have a hemoglobin value ≤ 10 g/dL on the screening laboratories.
Patients must have ≤ 10% blasts in the bone marrow and peripheral blood.
Patient must have a platelet counts > 50,000/microliters and absolute neutrophil counts (ANC) >500/microliters.
Patient must have adequate hepatic and renal functions, defined as serum bilirubin, serum glutamic-oxaloacetic transaminase (SGOT), and serum glutamate pyruvate transaminase (SGPT) ≤ 2 times the upper limit of normal (ULN), and creatinine ≤ 1.5 times the ULN.
Patient must have an ECOG score of ≤ 2.
The patient has a negative human immunodeficiency virus antibody (HIV) test result.

Exclusion Criteria:

A patient will be ineligible for study participation if any of the following criteria are met:

The patient has a history of an allergic reaction or significant sensitivity to Panhematin®.
The patient has taken or used any investigational drug or device in the 30 days prior to screening.
The patient has chronic myelomonocytic leukemia (CMML).
The patient has a history of deep vein thrombosis or known hypercoagulable state.
The patient has a history of a pre-existing medical condition that, in the opinion of the investigator, will interfere with the participation in the study.
The patient has poor peripheral venous access, if central venous access is not available.
The patient has an uncontrolled active infection.
The patient has positive test results for hepatitis B surface antigen, and hepatitis C virus antibody.
The patient has any other condition or prior therapy that, in the opinion of the Investigator, would make the patient unsuitable for the study.
Intervention: Oxcarbazepine
Trial phase: Not Applicable
ATC code: N03AF02
SMILES: NC(=O)N1c2ccccc2CC(=O)c2ccccc21
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 3
Group description: Oxcarbazepine is the active drug to be given to subjects in the experimental arm

Oxcarbazepine : Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the AM for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a CGI of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
Eligibility criteria:
Inclusion Criteria:

Subject has autism.
Subject is between five and seventeen years of age
Subject is not hospitalized.

Exclusion Criteria:

Subject has been diagnosed with a psychopathic disorder or a mood disorder, including depression or bipolar disorder.
Subject has displayed self-injurious behavior.
Subject has an active seizure disorder or epilepsy.
Subject has an unstable medical illness.
Subject has undergone brain injury.
Subject has a history of diabetes.
Subject has a history of prior treatment with oxcarbazepine of 600 mg/day for 6 weeks.
Subject has used other study drugs within the previous 30 days.
Subject is a pregnant female or unwilling to use acceptable contraception if sexually active.
Intervention: Testosterone
Trial phase: Not Applicable
ATC code: G03BA03 | G03EA02
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 47
Group description: androgel

androgel: androgel 1%
Eligibility criteria:
Inclusion Criteria:

Males with age 30-60 years inclusive.
PSA < 2.6 ng/ml or < 3.75 ng/ml with a negative prostate biopsy in the last 6 months.
IPSS ≤ 19. The lower age limit was decided on the fact that in our study on hypogonadotrophic hypogonadism in type 2 diabetic patients, the youngest subject was 31 years old. The upper age limit has been restricted to 60 to avoid including subjects with significant age-related declines in testosterone concentrations.Subjects on thiazolidinediones, statins, ACE inhibitors, angiotensin receptor blockers or antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the study. Subjects on insulin, metformin or sulfonylureas can participate in the study, provided that minimal changes are made to the doses during the study

Exclusion Criteria:

Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks; 2)Hemoglobin A1c >10%;
h/o prostate carcinoma;
Hepatic disease (transaminase > 3 times normal) or cirrhosis;
Renal impairment (serum creatinine > 1.5);
HIV or Hepatitis C positive status;
Participation in any other concurrent clinical trial;
Any other life-threatening, non-cardiac disease;
Use of over the counter health supplements which contain androgens;
Use of an investigational agent or therapeutic regimen within 30 days of study.
Use of testosterone in the past
Hematocrit > 50%.
Intervention: Aripiprazole
Trial phase: Not Applicable
ATC code: N05AX12
SMILES: O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 7
Group description: Subjects in the experimental group will receive Aripiprazole

Aripiprazole: Subjects under 40 kg will be started on 2.5mg per day of aripiprazole for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
Eligibility criteria:
Inclusion Criteria:

Meets DSM-IV, ADI-R criteria for autistic disorder.
Age 5-17 years.
Outpatients
Parent or legal guardian willing to sign informed consent.

Exclusion Criteria:

Subject has been diagnosed with a psychotic disorder (such as schizophrenia) or a mood disorder, including depression or bipolar disorder (manic depression).
Subject has caused visible harm to him/herself.
Subject has an active seizure disorder or epilepsy (seizures within the past year).
Subject has an unstable medical illness, including heart disease.
Subject has experienced brain injury.
Subject has a history of diabetes.
Subject reports significant improvement of autism symptoms and behaviors to current medication or other therapies.
Subject has a history of prior treatment with Aripiprazole of 5 mg/day or higher for 6 weeks.
Subject lives in a far away area and/or does not have regular access to transportation to the clinical facility.
Subject is a pregnant female or unwilling to use acceptable contraception if sexually active.
Intervention: (8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one;methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(E)-4-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]heptanoate
Trial phase: Not Applicable
SMILES: CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(c3ccc(N(C)C)cc3)CC21C.CCCCC(C)(O)CC=CC1C(O)CC(=O)C1CCCCCCC(=O)OC
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 16
Group description: Women in this group received mifepristone 200 mg orally followed by misoprostol 800 mcg buccally
Eligibility criteria:
Inclusion Criteria:

Age >18yrs, able to read and write English
Intrauterine gestations with anembryonic sac between 10 and 45mm or
10-15mm sac with no growth in three days or other radiologic signs of abnormal pregnancy such as irregular sac or debris within the gestational sac
An embryonic pole <30mm with no cardiac activity

Exclusion Criteria:

Intrauterine gestations with CRL <5mm or >30mm without cardiac activity
Incomplete abortion as defined as open cervix and large amount of cramping/bleeding
Hemodynamic instability and/or heavy vaginal bleeding
Hemoglobin less than or equal to 8
Inability to follow-up (ie, lack of transportation or access to telephone)
Bleeding disorder or taking anticoagulants
Prior medical or surgical treatment of the current pregnancy
Obvious Infection
Active Lactation
Allergy to mifepristone or misoprostol
Chronic corticosteroid use
Severe gastrointestinal disease (e.g inflammatory bowel disease, severe gastritis)
Intervention: Sildenafil Citrate
Trial phase: Phase 4
SMILES: CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 117
Group description: Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil citrate 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil citrate 100 mg PRN for the following four weeks.
Eligibility criteria:
Inclusion Criteria:

Documented Clinical diagnosis of Erectile Dysfunction (ED) by International Index of Erectile Function (IIEF) Erectile Function (EF) Domain score less than or equal to 25.
Subjects must be in a stable relationship

Exclusion Criteria:

Subject with resting sitting hypotension (BP <90/50 mmHg) or hypertension (BP>170/110 mmHg) and orthostatic hypotension.
Subjects receiving any PDE (Phosphodiesterase)-5 inhibitors within 4 weeks prior to the date of screening.
Subjects with severe hepatic impairment, a known history of retinitis pigmentare.
Subjects with significant cardiovascular disease in the last 3 months (per medical history.
Intervention: Gadobutrol
Trial phase: Phase 1
ATC code: V08CA09
SMILES: O=C([O-])CN1CCN(CC(=O)[O-])CCN(C(CO)C(O)CO)CCN(CC(=O)[O-])CC1.[Gd+3]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 46
Group description: Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
Eligibility criteria:
Inclusion Criteria:

Patients (male/ female) of specific age groups (2-6 years, 7-11 years, 12-17 years) who are scheduled to undergo Gadolinium (Gd)-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).

Exclusion Criteria:

Clinically unstable patients (e.g. intensive care unit)
Renal insufficiency
Patients undergoing a relevant change in chemotherapy </= 48 hours prior to and up to 24 hours after the administration of Gadovist.
Intervention: Gadobutrol
Trial phase: Phase 1
ATC code: V08CA09
SMILES: O=C([O-])CN1CCN(CC(=O)[O-])CCN(C(CO)C(O)CO)CCN(CC(=O)[O-])CC1.[Gd+3]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 44
Group description: Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
Eligibility criteria:
Inclusion Criteria:

Patients (male/ female) of specific age groups (2-6 years, 7-11 years, 12-17 years) who are scheduled to undergo Gadolinium (Gd)-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).

Exclusion Criteria:

Clinically unstable patients (e.g. intensive care unit)
Renal insufficiency
Patients undergoing a relevant change in chemotherapy </= 48 hours prior to and up to 24 hours after the administration of Gadovist.
Intervention: Gadobutrol
Trial phase: Phase 1
ATC code: V08CA09
SMILES: O=C([O-])CN1CCN(CC(=O)[O-])CCN(C(CO)C(O)CO)CCN(CC(=O)[O-])CC1.[Gd+3]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 48
Group description: Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
Eligibility criteria:
Inclusion Criteria:

Patients (male/ female) of specific age groups (2-6 years, 7-11 years, 12-17 years) who are scheduled to undergo Gadolinium (Gd)-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).

Exclusion Criteria:

Clinically unstable patients (e.g. intensive care unit)
Renal insufficiency
Patients undergoing a relevant change in chemotherapy </= 48 hours prior to and up to 24 hours after the administration of Gadovist.
Intervention: Gadobutrol
Trial phase: Phase 1
ATC code: V08CA09
SMILES: O=C([O-])CN1CCN(CC(=O)[O-])CCN(C(CO)C(O)CO)CCN(CC(=O)[O-])CC1.[Gd+3]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 138
Group description: Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
Eligibility criteria:
Inclusion Criteria:

Patients (male/ female) of specific age groups (2-6 years, 7-11 years, 12-17 years) who are scheduled to undergo Gadolinium (Gd)-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).

Exclusion Criteria:

Clinically unstable patients (e.g. intensive care unit)
Renal insufficiency
Patients undergoing a relevant change in chemotherapy </= 48 hours prior to and up to 24 hours after the administration of Gadovist.
Intervention: Memantine
Trial phase: Phase 4
ATC code: N06DA52 | N06DA53 | N06DX01
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 135
Group description: Memantine 20mg (10mg twice daily), oral administration for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Male and female outpatients, 50 years or older, native English speakers, meeting National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD with a Mini Mental State Examination (MMSE) score of 10 to 19 at Screening and Baseline

Exclusion Criteria:

Current Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition (DSM-IV) Axis I disorder other than AD
Previous imaging results not consistent with the diagnosis of AD
Modified Hachinski Ischemia Score greater than 4
Evidence of other neurologic disorders
Clinically significant systemic disease
A known or suspected history of alcohol or drug abuse in the past 5 years
Taking excluded medication
Previous treatment with commercial memantine
Intervention: Basaglar
Trial phase: Not Applicable
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NCC(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 17
Group description: Within subjects comparison; before and after treatment.

Beta-cell function measured with OGTT/hyperglycemic clamp
Eligibility criteria:
Inclusion Criteria:

Aim 1:

(non-diabetics)

male/female 30-65 yrs old,
free of active medical disease,
no history of diabetes.

(diabetics)

HbA1c=6.5-8.5,
treated with metformin, a sulfonylurea, or combination,
Stable body wt with BMI 28-40.
Aim 2: Same as above
Aim 3: Diabetic with HgA1c 8.0-9.5

Exclusion Criteria:

Aim 1: For both groups: no history of: pancreatitis, cardiac, gastrointestinal, renal or liver disease.
Aim 2: Same as above
Aim 3: Same as above, plus a diagnosis of incipient diabetic nephropathy severe nonproliferative, or proliferative retinopathy.
Intervention: CLOBETASOL PROPIONATE
Trial phase: Not Applicable
ATC code: D07AD01
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
Eligibility criteria:
Inclusion Criteria:

The presence of plaque-type psoriasis in areas of the trunk, buttocks, or extremities that are amenable to biopsy and evaluable disease in at least 2 cm target treatment sites separated by 1 cm
Age 18-80, both genders, all ethnicities
No contraindications to phototherapy or biopsy procedures
No topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 1 week prior to the study
No systemic psoriasis therapy for at least four weeks prior to the study
Able to give informed consent under IRB approval procedures

Exclusion Criteria:

Photosensitivity disorders
Active untreated diseases or medication usage which may interfere with UVB, wound healing, or immune function
Hypersensitivity to local anesthetic
Inability to provide informed consent
Pregnancy and /or lactating
Intervention: D-Pinitol
Trial phase: Phase 2
SMILES: COC1C(O)C(O)C(O)C(O)C1O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Subjects with Alzheimer's Disease

NIC5-15: a natural product, found in many foods and plants with mild insulin sensitizing effects
Eligibility criteria:
Inclusion Criteria:

NINCDS/ADRDA criteria for probable AD
MMSE between 12-27
Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist with stable dose for at least 12 weeks
Home monitoring available for supervision of medications
Caregiver available to accompany patient to all visits and willing to participate in study as informant
Fluent in English or Spanish
Medical stability for this study as confirmed by review of records, internist's physical exam, neurological exam, and laboratory tests
Stable doses of non-excluded medication
No evidence of hepatic insufficiency
Able to swallow oral medications
Ability to participate in the informed consent process

Exclusion Criteria:

History of Diabetes Mellitus (OGTT criteria) requiring treatment with an excluded antidiabetic medication (see below) or history of hypoglycemia
Active hepatic or renal disease
Cardiac disease including history of congestive heart failure or current treatment for CHF; history of recent myocardial infarction
Use of another investigational drug within the past two months
History of clinically significant stroke
History of seizure or head trauma with disturbance of consciousness within the past two years
Major mental illness including psychotic disorders, bipolar disorder, or major depressive episode within the past two years Medication Exclusion
Current use of oral hypoglycemic agents including sulfonylureas and meglintinides
Current use of a lipid-lowering agent (excluded from Study #1, see discussion below)
Current or past treatment with insulin for longer than two weeks
Current use of drugs with significant anticholinergic or antihistaminic properties
Intervention: Sunitinib
Trial phase: Phase 2
ATC code: L01EX01
SMILES: CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 83
Group description: Sunitinib 37.5 milligrams (mg) daily by oral capsule in continuous daily dose (CDD) schedule. Dose adjustments, if needed, included a reduction to 25mg daily or escalation to 50mg daily anytime after Week 12.
Eligibility criteria:
Inclusion Criteria:

Histologically or cytologically proven diagnosis of breast cancer
Metastatic or locally recurrent disease that is, in the opinion of the investigator, not amenable to resection or radiation therapy
Patients with at least one measurable lesion as per RECIST

Exclusion Criteria:

Inflammatory breast cancer
Prior treatment with VEGF inhibitors (unless in adjuvant setting at least 12 months ago)
Intervention: Lansoprazole
Trial phase: Phase 4
ATC code: A02BC03 | A02BC06 | A02BC53 | A02BD02 | A02BD03 | A02BD07 | A02BD09 | A02BD10
SMILES: Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1
Sex: All
Age groups: Child | Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 2
Group description: Lansoprazole: If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
Eligibility criteria:
Inclusion Criteria:

All healthy children ages 5-18 years scheduled for tonsillectomy and /or adenotonsillectomy for sleep disturbance secondary to airway obstruction at Children's Hospital Boston

Exclusion Criteria:

Patients on any medications other than the study drug (Lansoprazole or placebo), Amoxicillin®, and acetaminophen with or without codeine
An underlying medical condition which would necessitate an alteration in the anesthetic regimen
Patients allergic to any of the medications in the protocol
History of chronic tonsillitis
History of chronic pain conditions
History of active gastro-esophageal reflux disease
Surgery in addition to tonsillectomy/adenotonsillectomy (except for myringotomy)
Cognitive/developmental disorders
Inability to use a self-report pain scale